Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. STAT is hosting a virtual event tomorrow on the future of biosimilars. Check it out here.
VCs rush to invest in osteoporosis drugs
Developing drugs for brittle bones has long been a difficult endeavor, due to safety concerns and regulatory barriers. But now with new guidance from the FDA, pharma companies are returning to osteoporosis research, and investors are getting interested.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.